rtsn

What to Watch as Retension Pharmaceuticals Prices Its IPO

Retension Pharmaceuticals, Inc. (NASDAQ: RTSN) is expected to list on 2026-10-09 at a proposed price range of $11.00 to $13.00 per share. The company is offering 3,300,000 shares, with no market cap disclosed in the IPO calendar data. The setup is straightforward: a clinical-stage hypertension biotech with early pilot data and a Phase 2b/Phase 3 path ahead, but no product revenue yet and a long regulatory climb still in front of it.